Study 1 Clause Samples

Study 1. Students 1. Effectiveness 1 2. Satisfaction 0.337** 1 0.000 3. Purpose - Interactive 0.122* 0.601** 1 (question 1) 0.017 0.000 4. Purpose - Rehearse 0.397** 0.616** 0.352** 1 (question 4) 0.000 0.000 0.000 5. Purpose - Different 0.337** 0.464** 0.320** 0.562** 1 Approach (question 5) 0.000 0.000 0.000 0.000 6. Purpose - Gain Insight 0.375** 0.504** 0.306** 0.556** 0.574** 1 (question 6) 0.000 0.000 0.000 0.000 0.000 7. Purpose - Attention 0.295** 0.630** 0.398** 0.490** 0.393** 0.466** Paid (question 9) 0.000 0.000 0.000 0.000 0.000 0.000 1 Table 13 contains the mean scores and standard deviations of the different questions in the questionnaire. The means range between 2,77 and 4,23 and the standard deviation ranges between 0,694 and 1,0056. Figure 1 gives an overview on the general judgement of Bingo, as you can see 78,96% of the respondents thought that Bingo was successful to totally successful. Effectiveness 385 2,77 5 1 0,978 -4,533 0,000 Satisfaction 385 4,07 5 1 0,694 30,157 0,000 Purpose – Interactive 385 4,23 5 2 0,696 34,648 0,000 Purpose – Rehearse 383 3,77 5 1 0,919 16,285 0,000 Purpose – Different Approach 385 3,63 5 1 0,936 13,128 0,000 Purpose – Gain Insight 385 3,09 5 1 1,001 1,833 0,034 Purpose – Attention Paid 385 3,58 5 1 1,056 10,717 0,000 After analysing all the data of the survey (see Table 13), we can conclude that the Bingo game was successful in satisfying the students. On the contrary students do not find Bingo effective but this does not mean that Bingo will not increase the actual performance of the students. Further research is necessary to study the effect on their performance. In terms of different purposes for the Bingo game, it can be said that Bingo is well suited for rehearsing the material. It is also a good alternative to approach the material in a different way and it made the class more interactive. ▇▇▇▇▇ also helped the students to pay attention in class. For the purpose on gaining insight, the effect of the game was also significant. However, it should be noted that the p-value was higher (0,034) in comparison to the other purposes, which had a p- value of 0,000.
View Source
Study 1. For the open-ended question in study 1, the recommendations/criticisms of the students were first put into different categories: - A reward for the winners mentioned 30 times - To less time to solve the questions mentioned 5 times - Incorporate the smartphone mentioned 6 times - Positive reactions towards the game mentioned 12 times - More of those games mentioned 2 times Some of the positive reactions were: ‘very interactive’, ‘was very enjoyable’, ‘good PowerPoint’, ‘fun’, ‘perfect’, ‘good idea’ and ‘keep up the good work’. One student even made a comment that ▇▇▇▇▇ should take longer than it did, while another student found that the questions were good but that the game on its own was too time consuming. Other students suggested the idea of using their smartphone in the Bingo game or the creation of an online platform (like Kahoot). There was one student who suggested to use self-made cards. This is exactly what we did during the workshop. Another student suggested to introduce other games, which was something that we also did for the teachers. We also agree with the statement ‘not usable for teaching, but usable to repeat the course material’. This is something that was also proven by our questionnaire for the teachers, in which they claimed that the games were not suited to approach new material.
View Source
Study 1. Treatment-seeking Sample
View Source
Study 1 
View Source

Related to Study 1

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Study Design This includes a discussion of the evaluation design employed including research questions and hypotheses; type of study design; impacted populations and stakeholders; data sources; and data collection; analysis techniques, including controls or adjustments for differences in comparison groups, controls for other interventions in the State and any sensitivity analyses, and limitations of the study.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.